Department of Medicines Policy and Standards (PSM)

Priority Medicines for Europe and the World Project
"A Public Health Approach to Innovation"

(Updated 24 November 2005)


Priority Medicines for Europe and the World and Pharma Futures: One year on
23-25 November 2005

Executive Summary [doc 62KB] 
Final Report -- November 2004  [pdf 2.3MB]  
For contributions and comments
Presentations made at the STAKEHOLDERS MEETING FOR PRIORITY MEDICINES FOR EUROPE AND THE WORLD held at the Permanent Representation of the Netherlands to the EU, Hermann Debrouxlaan 48, Brussels, Belgium, on Monday 4 October 2004  
Programme and presentations for November 18th Meeting in the Hague (Pictures taken during the Meeting)
Press Responses
Pharma Futures link  (Report)


 Final Report 

Background Report  Annexes    Appendices



Chapter 1

Introduction to the Project
[doc 82KB]

To Section 1

To Section 1

Chapter 2

Background to Priority Medicines Project
[doc 86KB]

To Section 2

To Section 2

Chapter 3

Priority Setting
[doc 157KB]

To Section 3

To Section 3

Chapter 4

Methods Used in this Project
[doc 255KB]

To Section 4

Chapter 5

Preliminary Results
[doc 655KB]

To Section 5

Chapter 6

Priority Diseases and Reasons for Inclusion


Antibacterial Drug Resistance [doc 1.4MB]

To Section 6.1

To Section 6.1


Pandemic Influenza  [doc 346KB]

To Section 6.2


Cardiovascular Disease [doc 744KB]

To Section 6.3

To Section 6.3


Diabetes [doc 425KB]

To Section 6.4


Cancer and Cancer Therapeutics [doc 507KB]


Acute Stroke [doc 196KB]


HIV/AIDS: Opportunities to Address Pharmaceutical Gaps  
[doc 889KB]

To Section 6.7


Tuberculosis [doc 477KB] 

To Section 6.8

To Section 6.8


Neglected Diseases  [doc 1.1MB]

To Section 6.9 

To Section 6.9


Malaria  [doc 529KB]


To Section 6.10


Alzheimer Disease  [doc 1.1MB]

To Section 6.11


Osteoarthritis [doc 864KB]

To Section 6.12


Chronic Obstructive Pulmonary Disease [doc 316KB]


Alcohol Use Disorders: Alcoholic Liver Diseases and Alcohol Dependency  [doc 596KB]

To Section 6.14

To Section 6.14


Depression in Young People and the Elderly [doc 564KB] 

To Section 6.15


Post Partum Haemorrhage  [doc 84KB] 

To Section 6.16

To Section 6.16


Tobacco Use Cessation [doc 217KB] 

To Section 6.17

Chapter 7

Cross-Cutting Themes




Delivery Mechanisms [doc 166KB] 

To Section 7.1

To Section 7.1


Pharmaceuticals and the Elderly [doc 371KB] 


Pharmaceuticals and Children [doc 294KB] 


Pharmaceuticals and Women [doc 454KB] 


Orphan Diseases [doc 344KB] 

To Section 7.5

 Chapter 8

 New Approaches to Promoting Innovation

To Section 8


Public-Private Partnerships for Neglected Diseases: Opportunities to Address Pharmaceutical Gaps for Neglected Diseases
[doc 412KB]

To Section 8.1


Approach to the Valuation and Pricing of Future Medicines  
[doc 228KB]

To Section 8.2

To Section 8.2


Benefit, Risk and Innovation in Pharmaceutical Research and Development: Opportunities and Issues  
[doc 381KB]

To Section 8.3

To Section 8.3


Comparative Effectiveness of Medicines and Use of Head-to-Head Comparative Trials [doc 142KB]  


Technology Platform for the Pharmaceutical Industry

To Section 8.5

Chapter 9

Conclusions and Recommendations 




Priority Medicines for Europe and the World

© World Health Organization 2005

All rights reserved. No part of the contents of this CD-ROM may be reproduced, changed, adapted, translated, stored in a retrieval system or transmitted in any form or by any means without prior permission of the copyright holder, except to make a security backup. Requests for permissions, with a statement of the purpose and extent, should be addressed to Publications, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (fax: +41 22 791 4806; email:

The designations employed and the presentation of the material on this CD-ROM do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers and boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers? products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.

The World Health Organization does not warrant that the information contained on the CD-ROM is complete and correct. The Organization shall not be liable for any damages incurred as a result of use of the data or programs.

The procedures and programs used for access to or display of the data contained on the CD-ROM may not be reproduced, changed, adapted, translated, stored in a retrieval system (except for backup copies) or transmitted in any form or by any means without the prior permission of the copyright holder.

The named authors alone are responsible for the views expressed in this CD-ROM.



For further information please contact:

Last update:16-Nov-2006